These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 30983996)

  • 41. Pharmacoeconomics of Biosimilars: What Is There to Gain from Them?
    Araújo FC; Gonçalves J; Fonseca JE
    Curr Rheumatol Rep; 2016 Aug; 18(8):50. PubMed ID: 27402107
    [TBL] [Abstract][Full Text] [Related]  

  • 42. European Stakeholder Learnings Regarding Biosimilars: Part II-Improving Biosimilar Use in Clinical Practice.
    Barbier L; Simoens S; Vulto AG; Huys I
    BioDrugs; 2020 Dec; 34(6):797-808. PubMed ID: 33063267
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries.
    Gulácsi L; Brodszky V; Baji P; Rencz F; Péntek M
    Adv Ther; 2017 May; 34(5):1128-1144. PubMed ID: 28397080
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Switching between reference adalimumab and biosimilars in chronic immune-mediated inflammatory diseases: A systematic literature review.
    García-Beloso N; Altabás-González I; Samartín-Ucha M; Gayoso-Rey M; De Castro-Parga ML; Salgado-Barreira Á; Cibeira-Badia A; Piñeiro-Corrales MG; González-Vilas D; Pego-Reigosa JM; Martínez-López de Castro N
    Br J Clin Pharmacol; 2022 Feb; 88(4):1529-1550. PubMed ID: 34622969
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Optimizing use and addressing challenges to uptake of biosimilars.
    Leber MB
    Am J Manag Care; 2018 Nov; 24(21 Suppl):S457-S461. PubMed ID: 30452214
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Biosimilars for the Management of Inflammatory Bowel Diseases: Economic Considerations.
    Gulacsi L; Pentek M; Rencz F; Brodszky V; Baji P; Vegh Z; Gecse KB; Danese S; Peyrin-Biroulet L; Lakatos PL
    Curr Med Chem; 2019; 26(2):259-269. PubMed ID: 28393687
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Biosimilars in the Treatment of Inflammatory Bowel Disease: Supporting Evidence in 2017.
    Scott FI; Lichtenstein GR
    Curr Treat Options Gastroenterol; 2018 Mar; 16(1):147-164. PubMed ID: 29492747
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Use of biosimilars in the treatment of rheumatoid arthritis : An overview].
    Morf H; Witte T
    Z Rheumatol; 2022 Mar; 81(2):110-117. PubMed ID: 34825948
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Inflammatory diseases: Integrating biosimilars into clinical practice.
    Feldman SR
    Semin Arthritis Rheum; 2015 Jun; 44(6 Suppl):S16-21. PubMed ID: 26058549
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Real-world evidence of a successful biosimilar adoption program.
    Humphreys SZ
    Future Oncol; 2022 May; 18(16):1997-2006. PubMed ID: 35296160
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Price and Market Share Evolution of the Original Biologics and Their Biosimilars in Finland.
    Luukkanen SV; Tolonen HM; Airaksinen M; Saarukka LSM
    BioDrugs; 2022 Jul; 36(4):537-547. PubMed ID: 35793041
    [TBL] [Abstract][Full Text] [Related]  

  • 52. An online survey among US patients with immune-mediated conditions: Attitudes about biosimilars.
    Gibofsky A; Jacobson G; Franklin A; O'Hara-Levi S; Peyrin-Biroulet L; McGrath M; McCabe D
    J Manag Care Spec Pharm; 2023 Apr; 29(4):343-349. PubMed ID: 36989450
    [No Abstract]   [Full Text] [Related]  

  • 53. Biosimilars: Rationale and current regulatory landscape.
    Olech E
    Semin Arthritis Rheum; 2016 Apr; 45(5 Suppl):S1-10. PubMed ID: 26947438
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The changing landscape of biosimilars in rheumatology.
    Dörner T; Strand V; Cornes P; Gonçalves J; Gulácsi L; Kay J; Kvien TK; Smolen J; Tanaka Y; Burmester GR
    Ann Rheum Dis; 2016 Jun; 75(6):974-82. PubMed ID: 26964144
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Biosimilars in inflammatory bowel disease.
    Gargallo CJ; Lué A; Gomollón F
    Minerva Med; 2017 Jun; 108(3):239-254. PubMed ID: 28176515
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparative Safety Profiles of Oncology Biosimilars vs. Originators in Europe: An Analysis of the EudraVigilance Database.
    Nikitina V; Santi Laurini G; Montanaro N; Motola D
    Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509341
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Potential Cost Implications of Mandatory Non-Medical Switching Policies for Biologics for Rheumatic Conditions and Inflammatory Bowel Disease in Canada.
    Crosby M; Tadrous M; Gomes T
    Clin Pharmacol Ther; 2021 Mar; 109(3):739-745. PubMed ID: 32909249
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
    Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E
    BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The Great Debate With IBD Biosimilars: Con: Biosimilars Should Not Be Routinely Used as a First Line Biologic and Not Switched From Reference Biologics.
    Panaccione R
    Crohns Colitis 360; 2021 Jul; 3(3):otab038. PubMed ID: 36776671
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Recognizing and addressing challenges to the adoption of trastuzumab biosimilars and HER2-targeted therapies.
    Whalen J
    Am J Manag Care; 2020 Mar; 26(2 Suppl):S23-S31. PubMed ID: 32282172
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.